参考文献
［1］颜虹，夏结来，于莉莉.临床试验中适应性设计研究进展［J］.中华预防医学杂志，2008，42：16.
［2］范大超.临床试验方案的撰写——团队合作、质量控制及合约［J］.中国处方药，2009，91（12）：62-63.
［3］刘炳林.药物临床试验中疗效指标的选择［J］.中国新药杂志，2017，26（18）：2113-2120.
［4］潘长玉，李文慧，曾姣娥，等.阿格列汀治疗2型糖尿病的有效性与安全性［J］.中华内科杂志，2015，54（11）：949-953.
［5］Campbell G.Similarities and differences of Bayesian designs and adaptive designs for medical devices：a regulatory view［J］.Stat Biopharm Res，2013，5：356-368.
［6］Chow SC，Chang M.Adaptive design methods in clinical trials［M］.2nd ed.Boca Raton：Chapman&Hall/CRC，2012.
［7］Dixon WJ，Mood AM.A method for obtaining and analyzing sensitivity data［J］.Journal of the American Statistical Association，1948，43：109-126.
［8］FDA.Guidance for industry.Patient-reported outcome measures：use in medical product development to support labeling claims［R/OL］.（2009）［2019-12-16］.https：//www.fda.gov/media/77832/download.
［9］FDA.Surrogate endpoint resources for drug and biologic development［R/OL］.（2018）［2019-3-16］.https：//www.fda.gov/drugs/developmentapprovalprocess/developmentresources/ucm606684.htm.
［10］Friedman FL，Furberg CD，DeMets DL.Fundamentals of clinical trials［M］.4th ed.New York：Springer，2010.
［11］Gulley J.An open label phase I study to evaluate the safety and tolerability of GI-6301 vaccine consisting of whole，heat-killed recombinant saccharomyces cerevisiae（yeast）genetically modified to express brachyury protein in adults with solid tumors［R/OL］.（2016）［2019-3-16］.https：//clinicaltrials.gov/ct2/show/NCT01519817？term＝maximal＋tolerated＋dose&recrs＝e&type＝Intr&phase＝04&u＿sap＝Yes&rank＝6.
［12］Penel N，Kramar A.What does a modified-Fibonacci dose-escalation actually correspond to［J］.BMC Medical Research Methodology，2012，12（1）：103.
［13］Penta JS，Rozencweig M，Guarino AM.Mouse and large-animal toxicology studies of twelve antitumor agents：relevance to starting dose for Phase I clinical trials［J］.Cancer Chemotherapy&Pharmacology，1979，3（2）：97-101.
［14］Shih WJ.Plan to be flexible：a commentary on adaptive designs［J］.Biometrical J，2006，48：656-659.
［15］Storer BE.Design and analysis of phase I clinical trials［J］.Biometrics，1989，45（3）：925-937.
［16］Todd S，Stallard NA.New clinical trial design combining phases 2 and 3：sequential designs with treatment selection and a change of endpoint［J］.Drug Informat J，2005，39：109-118.